title: A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia.
authors.forename: Jirí
authors.initials: J
authors.lastname: Schwarz
authors.forename: Jana
authors.initials: J
authors.lastname: Marková
authors.forename: Sona
authors.initials: S
authors.lastname: Peková
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Trnková
authors.forename: Dana
authors.initials: D
authors.lastname: Sponerová
authors.forename: Petr
authors.initials: P
authors.lastname: Cetkovský
mesh_terms: D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D007958:Leukocyte Count; D008297:Male; D018365:Neoplasm, Residual / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D014212:Tretinoin; D000079982:Gemtuzumab